Clinical Trial Update: A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) [Phase 1]

View source ↗

Summary

A Phase 1b study to investigate the safety and tolerability of ARGX-119 in adults with DOK7-congenital myasthenic syndrome (CMS) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Myasthenic Syndrome

Drugs mentioned

• ARGX-119

Snippet

Sponsor: argenx | Conditions: Congenital Myasthenic Syndrome, CMS | Phase 1 | Status: RECRUITING